%0 Generic
%A Valladares-Ayerbes, M.
%A Safont, M. J.
%A Gonzalez-Flores, E.
%A Garcia-Alfonso, P.
%A Aranda Aguilar, E.
%A Lopez-Munoz, A. M.
%A Cirera-Nogueras, L.
%A Falco-Ferrer, E. 
%A Rodriguez-Salas, N
%A Aparicio, J.
%A Llanos, M.
%A Castillo-Trujillo, O.A.
%A Pimentel-Caceres, P.
%A Cruz-Hernandez, J. J.
%A Salgado-Fernandez. M.
%A Salud-Salvia, A.
%A Garcia-Carbonero, R.
%A Massuti-Sureda, B.
%A Vicente-Conesa, M. A. 
%A Lloansi-Vila, A.
%T Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)
%D 2021
%@ 0923-7534
%U https://hdl.handle.net/10668/25694
%X Tumor - tissue biopsy is the standard of care (SOC) to assess  RAS  & BRAF ms in mCRC pts. However, the analysis of circulating cfDNA has the advantage of evidencing genetic  tumor heterogeneity. We explored the occurrence of KRAS, NRAS and BRAF sequence variants (sv) using cfDNA in 1L SOC  RAS  wt mCRC pts. The concordance of  RAS  ms between tissue and cfDNA , and the association of cfDNA   RAS  ms and ORR were also explored.
%K Humans
%K Cell-Free Nucleic Acids
%K Standard of Care
%~